Sandy Macrae, Sangamo CEO (via website)
In five patients, Sangamo’s Fabry disease gene therapy appears to be working so far
While Sangamo’s sickle cell partnership with Sanofi ground to a halt earlier this year, the California biotech’s Fabry disease program, still in its early …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
